Newsletter Life Sciences
In this second edition of the newsletter, you’ll learn about Anvisa going 100% digital, meaning that, starting in March 2025, Anvisa will only receive documents electronically. We also talk about Anvisa’s operation that resulted in the shutdown of aesthetic clinics for serious irregularities, as well as the agency’s procedure that re-evaluated hair ointments, canceling 47 irregular products. In addition, Anvisa has approved 124 drugs for rare diseases in the last eight years, reinforcing its commitment to innovation. In the pharmaceutical area, the courts denied an injunction in a lawsuit filed by the Federal Council of Medicine against pharmacists prescribing contraceptives, guaranteeing the validity of the CFF resolution, while the Brazilian Prosecutor’s Office is investigating pharmacies for alleged misuse of customers’ personal data. The Federal Pharmacy Council has also authorized pharmacists to prescribe prescription drugs, expanding their role in health care. Finally, the Federal Council of Medicine is intensifying its studies on Artificial Intelligence in medicine, establishing guidelines for the safe and ethical use of these technologies.
Download the material: